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Bronchial Thermoplasty – 
Principles and Controversies 
Pulmonary Grand Rounds 
October 29, 2014 
David R. Manoff, M.D 
Objectives 
• Learn the indications and contraindications for bronchial 
thermoplasty 
• Develop a basic understanding of the controversies about, 
and the barriers to, the use of thermoplasty 
• Understand the peri-procedural care and follow-up of 
patients who receive bronchial thermoplasty 
Conflicts of interest 
• None 
Our patient: a 54 year-old woman who presents with 
difficult to control asthma 
• Initially presented in April 2014 for evaluation for bronchial 
thermoplasty 
• Diagnosed 12 years prior to visit 
• In year before presentation 
• Three exacerbations requiring systemic corticosteroids 
• Two hospitalizations for asthma exacerbations 
• Five ED visits 
• On Symbicort 160/4.5 HFA, Montelukast 10 mg PO daily, PRN 
Albuterol HFA, which she uses daily 
• Reports severe debility and unemployed for two months 
since last hospitalization 
• Past Medical History 
• GERD 
• Obstructive sleep apnea on CPAP 9 cm H2O 
• Social History 
• Lifetime non-smoker 
• Lives in a house in process of being recarpeted 
• Two birds (cockatiels), no other animals 
• Physical exam unremarkable 
• Spirometry 
• FEV-1 2.81 liters (114% predicted) 
• FVC 3.18 liters (106% predicted) 
• FEV-1/FVC ratio 80% 
 
 
Is the patient appropriate for proceeding 
with bronchial thermoplasty 
…but wait.  What is bronchial thermoplasty really? 
• Essentially, the application of radiofrequency to the proximal 
airways to ablate smooth muscle 
• Decrease airway hyperresponsiveness by decreasing the 
ability of smooth muscle to constrict leading to decreased 
resistance 
 
• FDA approval for patients 18 years-old and older with 
“severe and persistent asthma not well-controlled with 
inhaled corticosteroids and long-acting beta agonists” 
Iyer, VN, Lim, KG.  Chest (2014); 146: 17-21. 
What do the guidelines say? 
• ATS/ERS Consensus on treatment of severe asthma 
• “We recommend that bronchial thermoplasty is 
performed in adults with severe asthma only in the 
context of an Institutional Review Board-approved 
independent systematic registry or a clinical study 
(strong recommendation, very low quality evidence).” 
• Why? 
• Long term consequences unknown 
• Invasive procedure 
• Authors felt further characterization of subgroups needed 
Chung, et al. Eur Resp J (2014); 43: 343-73. 
The theory 
 
• Based on recognition that airway smooth muscle contractility 
leads to increased airway resistance and decreased diameter 
• 11-dog study using a graded methacholine challenge both 
pre-and-post RF ablation of proximal airways 
• All thermoplasty was performed in a single procedure 
Danek, CJ, et al.  J Appl Physiol (2004); 97: 1946-53. 


First human trials 
 
• 9 patient prospective trial of patients scheduled to undergo 
resection of known or suspected malignancy 
• Thermoplasty only performed in areas of lung to be resected 
• Tissue evaluated by histological examination after lung 
tissue resected 
 
Miller, JD, et al.  Chest (2005); 127: 1999-2006. 

• Again demonstrated minimal changes with RF ablation at 55O 
C but more marked changes at 65O C 
• Epithelium either normal (3/9 patients) or demonstrated 
sloughing to regeneration 
• Patient with shortest follow-up (5 days) had glandular 
necrosis 
• Non-infectious pneumonitis present in 27% of pathology 
sections but no evidence of infectious pneumonitis 
• Clinically, no post-procedural hemoptysis, infections, 
additional clinic/ER visits, no need for additional 
bronchodilators 
First studies in asthmatics 
• Cox (2006) 
• 16 patient prospective study of patients with stable, mild-
moderate asthma 
• No changes to medications or symptoms in six weeks prior to study 
• All patients pre-treated with corticosteroids 
• Three sessions per patient, each three weeks apart 
• One for each lower lobe 
• One for bilateral upper lobes 
• Right middle lobe not treated 
• Follow-up with chest X-ray, EKG, methacholine challenge 
Cox, G, et al.  Am J Resp Crit Care Med (2006); 173: 965-9. 
• Baseline pre-bronchodilator FEV-
1 maintained post-procedure 
• For Methacholine PC20 means 
• Baseline 0.92 mg/mL 
• 4.75 mg/mL at 12 weeks 
• 5.45 mg/mL at 1 year 
• 3.40 mg/mL at 2 years 
• At 12 weeks 5/16 patients did not 
demonstrate a 20% decrease in 
FEV-1 with 16 mg/mL of 
methacholine 

Moving to severe asthma – the AIR (1) Study – NEJM 
2007 
• Multicenter randomized control trial of ICS/LABA with or 
without thermoplasty 
• Adult patients with moderate-severe asthma 
• Must be on high dose inhaled corticosteroid to achieve control 
• Worsening of disease based on Asthma Control Questionnaire or 
morning peak flows if LABA removed from treatment regimen 
• All FEV-1s within 60-85% predicted 




The AIR-2 Trial (2010) 
• Large multi-center randomized, prospective trial for severe asthma 
with bronchial thermoplasty vs. sham procedure 
• Inclusion Criteria 
• Adults 18-65 requiring high-dose ICS and LABA 
• LTRAs, Omalizumab and low-dose (<10 mg/day) Prednisone allowed 
• Stable on therapy for four weeks 
• Baseline Asthma Quality of Life Questionnaire (AQLQ) score 6.25 or 
lower (higher=better quality of life) 
• Pre-bronchodilator FEV-1 at least 60% predicted 
• Documented airway hyperresponsiveness (by methacholine 
challenge) 
• Asthma symptoms at least two days per week 
• Non-smokers at least 1 year 
 
Castro, M, et al.  Am J Resp Crit Care Med (2010); 181: 116-124. 
• Exclusion Criteria 
• Documented emphysema 
• Use of immunosuppressants, anticoagulants, or beta-blockers 
• 3 or more hospital admissions for asthma 
• 3 or more lower respiratory tract infections 
• 4 or more pulse doses of oral steroids for exacerbations 
 
• All patients had three bronchoscopies performed three 
weeks apart; bronchoscopy team was unblinded 
• Follow-up visit clinicians were blinded to group 





• Adverse Events 
• During treatment, wheezing, 
airway irritation, URIs common 
• 8.4% of intervention group 
required admission during 
treatment phase (2% in sham 
group) 
• Worsening of asthma 
• Lower respiratory tract infection 
• Low post-procedural FEV-1 
 
Okay, it looks like it works… Why all the controversy? 
• Was it really necessary? 
• Is it safe after the immediate post-procedure period? 
• Does it really work for severe asthma? 
• Is it cost-effective? 
Long-term Follow-up of AIR-2 
• Wechsler (2013) 
• 162/190 post-bronchial thermoplasty patients from AIR-2 were 
followed on a 3-month interval after the first year 
• All patients maintained on controller medications 
• Each patient monitored by spirometry, ED visits, asthma 
exacerbations requiring steroids 
Wechsler, ME, et al.  J Allergy Clin Immunol (2013); 132: 1295-302. 
• Controller therapy use 
• At baseline 72% of patients were on two high-dose long-term 
therapies (ICS+LABA) with 28% being on 3 or more medications 
• At 5-year follow-up, 45/162 (28%) of patients to complete 
follow-up had at least 50% decrease in medications 
• 5/162 had increases in controller therapy 
Long-Term Outcomes 

Was it necessary? 
• AIR-2 required patients with high-dose ICS and LABA therapy 
to maintain symptom control 
• Hawkins (BMJ 2003) 
• 259 patient double-blinded RCT from Scotland of patients with 
asthma on at least 800 mcg/day inhaled Beclomethasone 
• Randomized to maintaining maintenance dose of ICS or 
decreasing by 50%  
Hawkins, G, et al.  BMJ (2003); 326: 1115-21. 

Will bronchial thermoplasty work for asthmatics with 
fixed airway obstruction 
• Maybe – No large scale trials 
• Doening (2013) 
• Eight-patient single center (University of Chicago) case series 




• At 15-week follow-up, no change in FEV-1 (p=0.4) 
• No increase in hospitalization rate (mean 2.88 ± 1.2 vs. 0.5 ± 0.33) 
Doening, et al.  J Asthma (2013); 50: doi 10.3109/02770903.2012.751997 
Pre-BD FEV1 (% predicted) 51.8 ± 8.6 
  Pre-BD FEV1 <50%, n 5 
ICS dose (mcg/day) 1000 
Other medications, n 
  LABA (≥100 mcg) 8 
  OCS 4 
  Leukotriene modifiers 6 
  Omalizumab 2 
  Methylxanthines 2 
  Anticholinergics 3 
OCS dose (mg/day) 27.5 ± 4.8 
SABA use (puffs/day) 6 ± 0.8 
Avg. night wakings 
(nights/week) 
4.5 ± 1.0 
Hospitalizations last year 
(total no.) 
23 ± 1.2 
eNO (ppb) 55 ± 17.4 
IgE (IU/mL) 155 ± 8.7 
Overnight observations, n 
  Total no. of events 11 
  Total no. of patients with 
an event 
5 
  Cause, n 
  Increased BD use 5 
  Wheezing 2 
  Lower respiratory tract 
infection 
2 
  Atelectasis 1 
  Hemoptysis 1 
Intubations, n 0 
NIPPV, n 0 
Deaths, n 0 
Economics of Bronchial Thermoplasty 
• Annual cost of asthma therapy is $3,300/patient (2002-2007) 
• 59% of children and 33% of adults with asthma missed school 
or work based on a 2008 study 
• In spite of FDA approval in 2010, no private insurance 
policies for coverage established 
• CMS definition of “reasonable and necessary” unclear 
• In 2007 (i.e. three years before AIR-2), multiple insurers had 
non-coverage policies for BT labelling it experimental/ 
investigational 
• Maintained after FDA approval 
Mahajan, AK, Hogarth, K.  Chest (2013); 144: 1051-4. 
• Thermoplasty originally given Category 3 (experimental, 
temporary) CPT codes 
• Category 1 CPT codes for current medical practice, generally 
recognized by all US insurers 
• Category 1 CPT codes for BT now recognized as of January 2013 
(codes 31660 and 31661) 
• California Technology Assessment Forum panel 3/2012 
• Third-party assessment agency for insurers 
• Found that BT met safety and efficacy criteria for approval 
 
• How much does thermoplasty cost to do? 
• Alair thermoplasty system (one-time purchase): $60,000 
• Alair thermoplasty catheters (one per procedure): $2,500 
• Relief of symptoms: priceless 
Is it potentially cost-saving? 
• 5-year budget analysis model of the asthmatic population of 
a district in Northern Italy 
• Based on analysis of standard care with Omalizumab vs. 
standard care and Omalizumab with the addition of 
bronchial thermoplasty 
• Demographics and patient numbers were estimated both on 
ED visits, specialist visits, hospitalizations, and previous 
population data 
• Used 3.4% risk of severe adverse events per BT procedure 
(based on AIR-2 data) 




Getting a patient approved for thermoplasty 
• Almost every patient will require an appeal process 
• Individual case review to establish necessity 
• Must be able to demonstrate 
• Diagnosis of asthma 
• On therapy that constitutes best care 
• Unable to achieve control of the disease with best control measures 
• In 2011, 40% of appeals were approved on first request 
• Increased to 60% in 2012 
Mahajan, AK, Hogarth, K.  Chest (2013); 144: 1051-4. 
Bronchial Thermoplasty – Periprocedural care 
• Pre-procedural protocol 
• Patient given high-dose oral steroid (Prednisone 50 mg/day) for 
1-3 days prior to the procedure, the day of procedure, and the 
day after 
• All patients should receive pre-procedural bronchodilator 
therapy (2.5-5 mg Albuterol or 3 mL DuoNeb) 
• Pre-procedural spirometry for baseline (no procedure if post-
bronchodilator FEV-1 <85% from baseline) 
• No apparent URI symptoms 
Mayse, ML, et al.  J Bronchol (2007); 14: 115-23. 
• Intraprocedure 
• Can be done under moderate sedation or general anesthesia 
• Both lower lobes done as separate procedures, upper lobes done 
as third procedure 
• If done under moderate sedation, liberal use of lidocaine at 
vocal cords, trachea, airways to be treated 
• Each segment is entered with the catheter and the array is 
activated at 5 mm intervals distalproximal 
• Oozing and secretions common, may require intraprocedural 
cleaning of array 
 
 
The thermoplasty procedure 

Post-procedural monitoring 
• All patients should be monitored for 4-6 hours post-
procedure 
• At three hours, patient should receive bronchodilator with 
repeat spirometry being performed at hour 4 post-procedure 
• Should not discharge if post-bronchodilator FEV-1 is <85% of 
pre-procedural baseline 
• Phone calls 1- and 3-days post-procedure 
• Follow-up office visit 2-3 weeks post-procedure for 
spirometry, assessment of symptoms, and to schedule next 
step of procedure 
Back to our patient 
• First bronchial thermoplasty performed of right lower lobe 
without immediate complication 
• Did reqiure additional six days of Prednisone 40 mg/day 
• At follow-up visit, reported mild improvement in asthma 
symptoms 
• After second thermoplasty (left lower lobe), patient 
reported significant decrease in rescue Albuterol use 
• After third thermoplasty, patient stated “I don’t think I still 
have asthma anymore.”  No longer carrying Albuterol inhaler 
• Nocturnal awakenings monthly from 2-3/night 
Conclusions 
• Bronchial thermoplasty is a new, emerging technology for the 
treatment of asthma which is difficult to control medically 
• While no long-term studies exist, it has been demonstrated to be 
safe at up to five years post-procedure 
• There may be a cost-savings over usual care associated with 
bronchial thermoplasty after the initial investment in the 
procedure 
• Bronchial thermoplasty is not a “cure-all” and patients will still 
have residual symptoms.  Careful patient selection is necessary to 
ensure safety and success of the procedure 
• Further studies are needed to determine the efficacy of the 
procedure with fixed obstruction 
Thank you! 
 
Questions? 
